Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.
Raltegravir is an HIV integrase inhibitor that is metabolized through glucuronidation by uridine diphosphate glucuronosyltransferase 1A1, and its use is anticipated in combination with atazanavir (a uridine diphosphate glucuronosyltransferase 1A1 inhibitor). Two pharmacokinetic studies of healthy subjects assessed the effect of multiple-dose atazanavir or ritonavir-boosted atazanavir on raltegravir levels in plasma. Atazanavir and atazanavir plus ritonavir modestly increase plasma levels of raltegravir.
Merck, Whitehouse Station, RY34-A500, PO Box 2000, Rahway, NJ 07065-0900, USA. marian_iwamoto@merck.com
Marian
M
Iwamoto
Larissa A
LA
Wenning
Goutam C
GC
Mistry
Amelia S
AS
Petry
Sarah Y
SY
Liou
Kaylan
K
Ghosh
Sheila
S
Breidinger
Neal
N
Azrolan
Maria J
MJ
Gutierrez
William E
WE
Bridson
Julie A
JA
Stone
Keith M
KM
Gottesdiener
John A
JA
Wagner
D000328:Adult; D019380:Anti-HIV Agents / Q000493:pharmacokinetics*; D000069446:Atazanavir Sulfate; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009842:Oligopeptides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D009930:Organic Chemicals / Q000008:administration & dosage / Q000493:pharmacokinetics*; D010919:Placebos / Q000008:administration & dosage; D010949:Plasma / Q000737:chemistry*; D011725:Pyridines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium
D019380:Anti-HIV Agents; D009842:Oligopeptides; D009930:Organic Chemicals; D010919:Placebos; D011725:Pyridines; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D000069446:Atazanavir Sulfate